Our Network Real-world evidence study shows the significant impact of hyperkalaemia on cardiorenal patient outcomes Tags: #RWE #Cardiometabolic #AstraZeneca AstraZeneca’s real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK).
